Enveric Biosciences
Enveric Biosciences is a biotechnology company focused on improving the quality of life for individuals affected by cancer treatment side effects and mental health disorders. The company aims to develop novel therapeutics using natural compounds, particularly cannabinoids, to address unmet medical needs. Enveric's lead program, EB-003, targets mental health issues such as depression, anxiety, and addiction by promoting neuroplasticity without causing hallucinations. Additionally, the company is advancing EB-002, a next-generation synthetic prodrug of psilocin, which is being investigated for its potential in treating psychiatric disorders. Through its innovative approach, Enveric Biosciences seeks to offer effective solutions for patients facing challenging health conditions.
MagicMed Industries Inc. is a biotechnology company based in Calgary, Canada, that specializes in developing psychedelic-derived medicinal products and consumer goods. Founded in 2020, the company focuses on creating a library of novel derivative molecules, particularly from psilocybin and other classic psychedelics such as N,N-dimethyltryptamine (DMT). Through its proprietary Psybrary, MagicMed aims to develop patented products that are intended to be more effective and safer for various psychological indications. By harnessing innovative processes and technologies, the company seeks to provide valuable solutions that traditional pharmaceutical and consumer goods companies may lack.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.